Provided by Tiger Trade Technology Pte. Ltd.

MannKind

5.78
+0.27004.90%
Post-market: 5.76-0.0232-0.40%19:59 EST
Volume:3.01M
Turnover:17.31M
Market Cap:1.77B
PE:59.05
High:5.86
Open:5.59
Low:5.53
Close:5.51
52wk High:6.51
52wk Low:3.38
Shares:307.07M
Float Shares:300.98M
Volume Ratio:0.70
T/O Rate:1.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0979
EPS(LYR):0.1000
ROE:32.74%
ROA:9.95%
PB:-39.84
PE(LYR):57.80

Loading ...

The Bull Case For MannKind (MNKD) Could Change Following FDA-Backed Afrezza Dosing Label Update

Simply Wall St.
·
Jan 31

BUZZ-U.S. STOCKS ON THE MOVE-US natgas companies

Reuters
·
Jan 26

MannKind Price Target Maintained With a $11.00/Share by HC Wainwright & Co.

Dow Jones
·
Jan 26

MannKind Shares Rise 5% Premarket After US FDA Updates Label for Inhaled Insulin Afrezza

THOMSON REUTERS
·
Jan 26

BUZZ-U.S. STOCKS ON THE MOVE-Baker Hughes, Allied Gold Corp, MannKind Corp

Reuters
·
Jan 26

MannKind receives FDA approval for Afrezza dosage label

TIPRANKS
·
Jan 26

BRIEF-MannKind Announces FDA Approval of Updated Afrezza Label Providing Starting Dose Guidance when Switching from Multiple Daily Injections (MDI) or Insulin Pump Mealtime Therapy

Reuters
·
Jan 26

MannKind Announces FDA Approval of Updated Afrezza® Label Providing Starting Dose Guidance When Switching From Multiple Daily Injections (Mdi) or Insulin Pump Mealtime Therapy

THOMSON REUTERS
·
Jan 26

6 stocks and ETFs that these unsung market heroes see outperforming in 2026

Dow Jones
·
Jan 18

MannKind Targets Newly Diagnosed Youth With Afrezza: What Investors Should Watch

TIPRANKS
·
Jan 17

6 stocks and ETFs that these unsung market heroes see outperforming in 2026

Dow Jones
·
Jan 13

How 2026 FDA Decisions on Afrezza and FUROSCIX At MannKind (MNKD) Have Changed Its Investment Story

Simply Wall St.
·
Jan 10

Stuart A. Tross, Chief People & Workplace Officer, Reports Disposal of MannKind Corporation Common Shares

Reuters
·
Jan 10

Assessing MannKind (MNKD) Valuation As Regulatory Catalysts And Pipeline Updates Draw Investor Attention

Simply Wall St.
·
Jan 09

Multiple 2026 Regulatory, Pipeline, and Partnership Catalysts Underscore MannKind’s Underappreciated Growth Potential and Support Reiterated Buy Rating

TIPRANKS
·
Jan 09

MannKind shares not pricing in ‘multiple tailwinds,’ says H.C. Wainwright

TIPRANKS
·
Jan 09

BRIEF-Mannkind Provides Business Updates And 2026 Growth Drivers

Reuters
·
Jan 08

MannKind Reports Record Q4 Revenue and Highlights 2026 Growth Drivers

Reuters
·
Jan 08

Press Release: MannKind Provides Business Updates and 2026 Growth Drivers

Dow Jones
·
Jan 08

MannKind Corporation Secures Five New U.S. Patents for FUROSCIX ReadyFlow Autoinjector

Reuters
·
Dec 23, 2025